News & Events

• December 15, 2022
  

  Register Now: Critical Path to Women Leading in Science

    Date: Feb 6, 2022 | 1:30 PM Eastern Time (US and Canada) Please join C-Path for a 90-minute roundtable discussing the Critical Path Institute’s programs and consortia, highlighted by various women leaders at this public-private partnership. The team will discuss how C-Path contributes to transforming and accelerating the medical product development process, as well......
• December 14, 2022
  

  View Now | Shared Stewardship in Collaborative Curation of Rare Disease Datasets

  In this talk, we will discuss some of the best practices and collaborative approaches utilized by NORD and C-Path. From collection through curation, we will demonstrate the importance of data stewardship and its consistency throughout.

• September 13, 2022 - September 14, 2022
  

  View Now | 2022 RDCA-DAP Workshop, September 13-14

  Since its launch in 2019, the Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) has established itself as the leading platform to accelerate rare disease treatment innovation. Join us this September as we bring rare disease stakeholders together for next-level platform demonstrations and case studies, industry expert presentations, panel discussions and more. Attendees of......
• November 10, 2021
  

  View Now | RDCA-DAP Professional Webinar Series: RDCA-DAP Data Ingestion and Curation Process

  In this month’s webinar, describes RDCA-DAP’s data management practices and use of ontologies, with an emphasis on how the data ingestion and curation processes increase the value of patients’ data.

• October 27, 2021
  

  View Now | RDCA-DAP Professional Webinar Series: RDCA-DAP Collaboration with Clinerion for Real World Data Solutions

  In this webinar, Clinerion scientists will present an existing rare disease use case showcasing Clinerion predictive modeling efforts and discuss how collaboration with RDCA-DAP will leverage data from both platforms, improving the generalizability of such models. Audience discussion and Q&A will be included.